MX2019014450A - Vacuna contra la enteritis necrotica en aves de corral. - Google Patents

Vacuna contra la enteritis necrotica en aves de corral.

Info

Publication number
MX2019014450A
MX2019014450A MX2019014450A MX2019014450A MX2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A MX 2019014450 A MX2019014450 A MX 2019014450A
Authority
MX
Mexico
Prior art keywords
pilus
poultry
polypeptide
vaccine against
necrotic enteritis
Prior art date
Application number
MX2019014450A
Other languages
English (en)
Spanish (es)
Inventor
Gong Jianhua
Lepp Dion
Original Assignee
Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food filed Critical Her Majesty The Queen In Right Of Canada As Represented By The Mini Of Agriculture And Agri Food
Publication of MX2019014450A publication Critical patent/MX2019014450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2019014450A 2017-05-31 2018-05-31 Vacuna contra la enteritis necrotica en aves de corral. MX2019014450A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513001P 2017-05-31 2017-05-31
PCT/CA2018/050643 WO2018218360A1 (en) 2017-05-31 2018-05-31 Vaccine against necrotic enteritis in poultry

Publications (1)

Publication Number Publication Date
MX2019014450A true MX2019014450A (es) 2020-02-10

Family

ID=64454163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014450A MX2019014450A (es) 2017-05-31 2018-05-31 Vacuna contra la enteritis necrotica en aves de corral.

Country Status (8)

Country Link
US (2) US11318194B2 (https=)
EP (1) EP3630800A4 (https=)
JP (2) JP2020527051A (https=)
CN (1) CN110691787A (https=)
BR (1) BR112019025019A2 (https=)
CA (1) CA3064461A1 (https=)
MX (1) MX2019014450A (https=)
WO (1) WO2018218360A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234130A (zh) * 2021-05-24 2021-08-10 安徽医科大学第四附属医院 一种卡氏肺孢子菌重组蛋白及其制备方法与应用
WO2025199604A1 (en) * 2024-03-27 2025-10-02 Université de Montréal Recombinant vaccine proteins for the prevention of avian necrotic enteritis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) * 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
AU6094000A (en) * 1999-07-13 2001-01-30 Med Immune, Inc. Donor strand complemented pilin and adhesin broad-based vaccines
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
WO2007116322A2 (en) * 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
US7745175B2 (en) * 2006-10-27 2010-06-29 Dow Agrosciences Llc Polynucleotides encoding Clostridium perfringens alpha toxin proteins
US20100062025A1 (en) * 2006-11-20 2010-03-11 Intervet International B.V. Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine
US20110097360A1 (en) * 2007-05-25 2011-04-28 Claudio Donati Streptococcus pneumoniae pilus antigens
PL2164862T3 (pl) * 2007-06-08 2015-12-31 Australian Poultry Crc Pty Ltd Toksyna netb z clostridium
EP2162150A4 (en) * 2007-06-22 2011-10-12 Univ Guelph VACCINE AGAINST CLOSTRIDIUM PERFRINGENS
WO2011113801A1 (en) * 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
AR099470A1 (es) * 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
FR3065623B1 (fr) * 2017-04-28 2021-07-09 Roquette Freres Albumines de pois ameliorees, procede d'obtention et leurs applications
MX2021000184A (es) * 2018-07-05 2021-05-12 Novobind Livestock Therapeutics Inc Anticuerpos contra agentes patogenos en aves de corral y sus aplicaciones.

Also Published As

Publication number Publication date
JP2023090702A (ja) 2023-06-29
RU2019137515A3 (https=) 2021-12-03
EP3630800A1 (en) 2020-04-08
CA3064461A1 (en) 2018-12-06
US11318194B2 (en) 2022-05-03
BR112019025019A2 (pt) 2020-06-30
US20200093913A1 (en) 2020-03-26
EP3630800A4 (en) 2021-03-24
CN110691787A (zh) 2020-01-14
WO2018218360A1 (en) 2018-12-06
US20220226455A1 (en) 2022-07-21
JP2020527051A (ja) 2020-09-03
RU2019137515A (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
PH12021550542A1 (en) Multivalent pneumococcal vaccines
EA201691993A1 (ru) Вакцина к вирусу эпидемической диареи свиней
EP4458975A3 (en) Hbv vaccines and methods treating hbv
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
PH12021551816A1 (en) Inactivated apxia, apxiia and apxiiia toxins
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
WO2019028396A8 (en) Induction of protective immunity against antigens
MX2019000725A (es) Composiciones de vacuna para tratamiento de virus zika.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2018008529A (es) Virus de la tilapia de tipo ortomixo.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
HK1249431A1 (zh) 修饰的酵母-短尾畸形(brachyury)免疫治疗组合物
MY179251A (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
DK3501535T5 (da) Profylaktisk eller terapeutisk fremgangsmåde til svinepidemi-diarrévirus, vaccine og vaccinekit
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
MX2019014450A (es) Vacuna contra la enteritis necrotica en aves de corral.
EA201892003A1 (ru) Лечение атопического дерматита собак
WO2020012428A8 (en) New vaccines against avian reoviruses
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy